70 results
Keyword Advagraf Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Advagraf
tacrolimus, Graft Rejection
Date of authorisation: 23/04/2007, Revision: 25, Authorised, Last updated: 15/11/2022Advagraf Host vs Graft Reaction Transplantation … part of the EPAR). What is Advagraf? Advagraf is a medicine containing … over a few hours. What is Advagraf used for Advagraf is used in adult patients … -
List item
Press release: European Medicines Agency agrees to precautionary recall of Advagraf 0.5 mg capsule batches
CHMP, Last updated: 20/10/2011to precautionary recall of Advagraf 0.5 mg capsule batches … to precautionary recall of Advagraf 0.5 mg capsule batches … to precautionary recall of Advagraf 0.5 mg capsule batches … -
List item
Human medicine European public assessment report (EPAR): Tacforius
tacrolimus monohydrate, Liver Transplantation; Kidney Transplantation
Date of authorisation: 08/12/2017,
, Revision: 7, Authorised, Last updated: 10/01/2023
European Union (EU) called Advagraf. How is Tacforius used? Tacforius … with the reference medicine, Advagraf, and do not need to be repeated … and to be bioequivalent to Advagraf. Therefore, the Agency’s … -
List item
Human medicine European public assessment report (EPAR): Envarsus
tacrolimus, Graft Rejection
Date of authorisation: 18/07/2014, Revision: 12, Authorised, Last updated: 23/01/2023medicine for Envarsus is Advagraf. How is Envarsus used? Envarsus … to the reference medicine Advagraf, the applicant provided comparative … provided comparative data on Advagraf. In addition, because of the … -
List item
National expert: Stefan Strasser, Austrian Medicines and Medical Devices Agency (updated)
- Declaration of interests - 80.93 KB | PDF
- Curriculum Vitae - 18.65 KB | PDF
IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED … INVESTIGATING RENAL FUNCTION IN AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011
CHMP, Last updated: 21/10/2011Marketing authorisation holder Advagraf tacrolimus Astellas Pharma … -
List item
Human medicine European public assessment report (EPAR): Modigraf
tacrolimus, Graft Rejection
Date of authorisation: 15/05/2009, Revision: 18, Authorised, Last updated: 15/11/2022 -
List item
Human medicine European public assessment report (EPAR): Lupkynis
Voclosporin, Lupus Nephritis
Date of authorisation: 15/09/2022,
, Revision: 1, Authorised, Last updated: 07/02/2023
-
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 17/03/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/03/2022 to 10/03/2022, Last updated: 22/11/2022ciclosporin (NAP); tacrolimus - ADVAGRAF (CAP) - EMEA/H/C/000712/SDA/0 … -
List item
Committee for Medicinal Products for Human Use (CHMP): 10-13 October 2022
European Medicines Agency, Amsterdam, the Netherlands, from 10/10/2022 to 13/10/2022, Last updated: 23/11/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 29 November-2 December 2021
European Medicines Agency, Amsterdam, the Netherlands, from 29/11/2021 to 02/12/2021, Last updated: 04/10/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 August 2022
Written procedure, from 16/08/2022 to 19/08/2022, Last updated: 04/10/2022 -
List item
CHMP: Agendas, minutes and highlights
Last updated: 08/02/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 June 2022
European Medicines Agency, Amsterdam, the Netherlands, from 20/06/2022 to 23/06/2022, Last updated: 18/08/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 26-29 September 2022
European Medicines Agency, Amsterdam, the Netherlands, from 26/09/2022 to 29/09/2022, Last updated: 04/07/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 February 2021
European Medicines Agency, Amsterdam, the Netherlands, from 22/02/2021 to 25/02/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 May 2022
European Medicines Agency, Amsterdam, the Netherlands, from 16/05/2022 to 19/05/2022, Last updated: 12/08/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 April 2022
European Medicines Agency, Amsterdam, the Netherlands, from 19/04/2022 to 22/04/2022, Last updated: 12/08/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2022 to 24/03/2022, Last updated: 12/08/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 26-29 October 2020
Virtual meeting, from 26/10/2020 to 29/10/2020, Last updated: 08/01/2021EPIDYOLEX (CAP); tacrolimus - ADVAGRAF (CAP), ENVARSUS (CAP), MODIGRAF … -
List item
Committee for Medicinal Products for Human Use (CHMP): 11-14 October 2021
European Medicines Agency, Amsterdam, the Netherlands, from 11/10/2021 to 14/10/2021, Last updated: 20/01/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 February 2021
European Medicines Agency, Amsterdam, the Netherlands, from 08/02/2021 to 11/02/2021, Last updated: 08/02/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 21/06/2021 to 24/06/2021, Last updated: 07/12/2021 -
List item
Parallel distribution: Regulatory and procedural guidance
Last updated: 09/06/2021